Binding models of reversible inhibitors to type-B monoamine oxidase

被引:23
|
作者
Carrieri, A
Carotti, A
Barreca, ML
Altomare, C
机构
[1] Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy
[2] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy
关键词
monoamine oxidase-B; reversible MAO-B inhibitors; three-dimensional quantitative structure-activity; relationships; docking calculations;
D O I
10.1023/A:1023815426730
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interest in the inhibitors of type-B monoamine oxidase has grown in recent years, due to the evidence for multiple roles of one such agent ( selegiline) in the pharmacological management of neurodegenerative disorders. A set of 130 reversible and selective inhibitors of MAO-B ( including tetrazole, oxadiazolone, and oxadiazinone derivatives) were taken from the literature and subjected to a three-dimensional quantitative structure - activity relationship (3D-QSAR) study, using CoMFA and GOLPE procedures. The steric and lipophilic fields, alone and in combination, provided us with informative models and satisfactory predictions (q(2) = 0.73). The validity of these models was checked against the 3D X-ray structure of human MAO-B. Flexible docking calculations, performed by using a new approach which took advantage from QXP and GRID computational tools, showed the diverse inhibitors to interact with MAO-B in a similar binding mode, irrespective of the heterocycle characterizing them. A significant trend of correlation was observed between estimated energies of the complexes and the experimental inhibition data.
引用
收藏
页码:769 / 778
页数:10
相关论文
共 50 条
  • [21] PHARMACOLOGY OF REVERSIBLE AND SELECTIVE INHIBITORS OF MONOAMINE-OXIDASE TYPE-A
    FINBERG, JPM
    ACTA PSYCHIATRICA SCANDINAVICA, 1995, 91 : 8 - 13
  • [22] Activation of monoamine oxidase type-B by aluminum in rat brain homogenate
    Zatta, P
    Zambenedetti, P
    Milanese, M
    NEUROREPORT, 1999, 10 (17) : 3645 - 3648
  • [23] FOCUS ON SELEGILINE - A SELECTIVE MONOAMINE-OXIDASE TYPE-B INHIBITOR
    KANDO, JC
    KALUNIAN, DA
    HOSPITAL FORMULARY, 1990, 25 (08): : 849 - &
  • [24] GONADAL INFLUENCES ON THE INHIBITION OF MONOAMINE-OXIDASE TYPE-B ACTIVITY
    VACCARI, A
    BIASSONI, R
    JOURNAL OF NEUROSCIENCE RESEARCH, 1982, 8 (01) : 13 - 19
  • [25] TITRATION OF HUMAN-BRAIN TYPE-B MONOAMINE-OXIDASE
    FOWLER, CJ
    WIBERG, A
    ORELAND, L
    WINBLAD, B
    NEUROCHEMICAL RESEARCH, 1980, 5 (07) : 697 - 708
  • [26] Chromanones: selective and reversible monoamine oxidase B inhibitors with nanomolar potency
    Lan, Jin-Shuai
    Xie, Sai-Sai
    Huang, Ming
    Hu, Ya-Jian
    Kong, Ling-Yi
    Wang, Xiao-Bing
    MEDCHEMCOMM, 2015, 6 (07) : 1293 - 1302
  • [27] Monoamine oxidase A and B inhibitors
    Jegham, S
    George, P
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (09) : 1143 - 1150
  • [28] MONOAMINE-OXIDASE INHIBITORS - REVERSIBLE AND IRREVERSIBLE
    RUDORFER, MV
    PSYCHOPHARMACOLOGY BULLETIN, 1992, 28 (01) : 45 - 57
  • [29] THE PHARMACOLOGY OF REVERSIBLE MONOAMINE-OXIDASE INHIBITORS
    AMREIN, R
    ALLEN, SR
    GUENTERT, TW
    HARTMANN, D
    LORSCHEID, T
    SCHOERLIN, MP
    VRANESIC, D
    BRITISH JOURNAL OF PSYCHIATRY, 1989, 155 : 66 - 71
  • [30] Reversible inhibitors of monoamine oxidase A in anxiety disorders
    Buller, R
    CLINICAL NEUROPHARMACOLOGY, 1995, 18 : S38 - S44